BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 28423088)

  • 1. The epidemiology of cryptococcosis and the characterization of Cryptococcus neoformans isolated in a Brazilian University Hospital.
    Aguiar PADF; Pedroso RDS; Borges AS; Moreira TA; Araújo LB; Röder DVDB
    Rev Inst Med Trop Sao Paulo; 2017 Apr; 59():e13. PubMed ID: 28423088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
    Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
    Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
    Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
    J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil.
    Favalessa OC; de Paula DA; Dutra V; Nakazato L; Tadano T; Lazera Mdos S; Wanke B; Trilles L; Walderez Szeszs M; Silva D; Hahn RC
    J Infect Dev Ctries; 2014 Aug; 8(8):1037-43. PubMed ID: 25116671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility.
    Liaw SJ; Wu HC; Hsueh PR
    Clin Microbiol Infect; 2010 Jun; 16(6):696-703. PubMed ID: 19694765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization and antifungal susceptibility of Cryptococcus neoformans strains collected from a single institution in Lima, Peru.
    Bejar V; Tello M; García R; Guevara JM; Gonzales S; Vergaray G; Valencia E; Abanto E; Ortega-Loayza AG; Hagen F; Gutierrez EL
    Rev Iberoam Micol; 2015; 32(2):88-92. PubMed ID: 25556051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan.
    Chen YC; Chang SC; Shih CC; Hung CC; Luhbd KT; Pan YS; Hsieh WC
    Diagn Microbiol Infect Dis; 2000 Mar; 36(3):175-83. PubMed ID: 10729660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular epidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian city, Rio de Janeiro.
    Igreja RP; Lazéra Mdos S; Wanke B; Galhardo MC; Kidd SE; Meyer W
    Med Mycol; 2004 Jun; 42(3):229-38. PubMed ID: 15283237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil.
    Souza LK; Souza Junior AH; Costa CR; Faganello J; Vainstein MH; Chagas AL; Souza AC; Silva MR
    Mycoses; 2010 Jan; 53(1):62-7. PubMed ID: 19500261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents.
    Poonwan N; Mikami Y; Poosuwan S; Boon-Long J; Mekha N; Kusum M; Yazawa K; Tanaka R; Nishimura K; Konyama K
    Eur J Epidemiol; 1997 Apr; 13(3):335-40. PubMed ID: 9258534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
    Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
    Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
    Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
    Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal.
    Capoor MR; Mandal P; Deb M; Aggarwal P; Banerjee U
    Mycoses; 2008 May; 51(3):258-65. PubMed ID: 18399907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates.
    Arsic Arsenijevic V; Pekmezovic MG; Meis JF; Hagen F
    Mycoses; 2014 Jun; 57(6):380-7. PubMed ID: 24438323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.
    González GM; Casillas-Vega N; Garza-González E; Hernández-Bello R; Rivera G; Rodríguez JA; Bocanegra-Garcia V
    Folia Microbiol (Praha); 2016 Jan; 61(1):51-6. PubMed ID: 26109075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
    Li M; Liao Y; Chen M; Pan W; Weng L
    Braz J Infect Dis; 2012; 16(2):175-9. PubMed ID: 22552461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.